Reflow Medical gets FDA commercial clearance for coraCatheters

Reflow Medical has obtained commercial clearance from the US Food and Drug Administration (FDA) for its coraCatheters range of microcatheters.

These specialized devices are designed to access and navigate complex and challenging lesions during percutaneous coronary interventions.

The coraCatheters series is the latest addition to the portfolio of the American medical equipment manufacturer, which already includes the Wingman and Spex Catheters. With a focus on the coronary space, Reflow Medical is said to be expanding its sales team to provide support for both current and future innovations.

The coraCatheters line features the coraFlex microcatheter, equipped with an integrated flexible polymer tip that enables precise navigation through intricate anatomies. It offers optimal movement and support for guidewires.

Reflow Medical obtains FDA commercial clearance for coraCatheters. Image courtesy of Business Wire.

Additionally, the coraForce microcatheter, specifically designed for coronary disease treatment, incorporates a metallic tip. This feature maximizes tip force while minimizing fatigue, providing enhanced pushability, support, and a low-profile design throughout the procedure, said the medical equipment manufacturer.

Reflow Medical’s coraCross Crossing device utilizes their patented bevel-extension technology, specifically adapted to penetrate heavily calcified caps.

With three to four times the tip force compared to other polymer catheters, this device can be activated and advanced to achieve exceptional penetration and trackability during the procedure.

lesions, Reflow Medical, US FDA, US Food and Drug Administration, USA